CA125

Summary

Gene Symbol: CA125
Description: mucin 16, cell surface associated
Alias: CA125, mucin-16, CA125 ovarian cancer antigen, ovarian cancer-related tumor marker CA125, ovarian carcinoma antigen CA125
Species: human
Products:     CA125

Top Publications

  1. Caffery B, Joyce E, Heynen M, Jones L, Ritter R, Gamache D, et al. MUC16 expression in Sjogren's syndrome, KCS, and control subjects. Mol Vis. 2008;14:2547-55 pubmed
    ..The relationship of tear flow and soluble MUC16 concentration was also measured...
  2. Higashi M, Yamada N, Yokoyama S, Kitamoto S, Tabata K, Koriyama C, et al. Pathobiological implications of MUC16/CA125 expression in intrahepatic cholangiocarcinoma-mass forming type. Pathobiology. 2012;79:101-6 pubmed publisher
    MUC16 carries the peptide epitope CA125, which is well known as a marker of ovarian cancer. High serum levels of MUC16 (CA125) have been reported not only in patients with ovarian cancer but also in patients with liver diseases...
  3. Seelenmeyer C, Wegehingel S, Lechner J, Nickel W. The cancer antigen CA125 represents a novel counter receptor for galectin-1. J Cell Sci. 2003;116:1305-18 pubmed
    b>CA125 is an ovarian cancer antigen whose recently elucidated primary structure suggests that CA125 is a giant mucin-like glycoprotein present on the cell surface of tumor cells...
  4. ARGUESO P, Spurr Michaud S, Russo C, Tisdale A, Gipson I. MUC16 mucin is expressed by the human ocular surface epithelia and carries the H185 carbohydrate epitope. Invest Ophthalmol Vis Sci. 2003;44:2487-95 pubmed
    ..to determine whether the H185 antibody recognizes the recently cloned membrane-associated mucin MUC16 (formerly CA125 antigen)...
  5. Huhtinen K, Suvitie P, Hiissa J, Junnila J, Huvila J, Kujari H, et al. Serum HE4 concentration differentiates malignant ovarian tumours from ovarian endometriotic cysts. Br J Cancer. 2009;100:1315-9 pubmed publisher
    ..We, thus, analysed serum HE4 concentrations together with a tumour marker CA125 in serum samples of women diagnosed with various types of endometriosis, endometrial cancer or ovarian cancer, and ..
  6. ARGUESO P, Guzman Aranguez A, Mantelli F, Cao Z, Ricciuto J, Panjwani N. Association of cell surface mucins with galectin-3 contributes to the ocular surface epithelial barrier. J Biol Chem. 2009;284:23037-45 pubmed publisher
    ..Taken together, these results suggest that galectin-3 plays a key role in maintaining mucosal barrier function through carbohydrate-dependent interactions with cell surface mucins. ..
  7. Chen S, Dallas M, Balzer E, Konstantopoulos K. Mucin 16 is a functional selectin ligand on pancreatic cancer cells. FASEB J. 2012;26:1349-59 pubmed publisher
    ..affinity chromatography in conjunction with tandem mass spectrometry and bioinformatics tools, we identified mucin 16 (MUC16) as a novel selectin ligand expressed by metastatic pancreatic cancer cells...
  8. Bouanene H, Hadj Kacem H, Ben Fatma L, Ben Limem H, Ben Ahmed S, Yakoub S, et al. Polymorphisms in the MUC16 gene: potential implication in epithelial ovarian cancer. Pathol Oncol Res. 2011;17:295-9 pubmed publisher
    ..We aimed also to test the association between these tags SNPs and elevated level of the protein CA125. We analyzed a collection of 117 cases...
  9. Akita K, Tanaka M, Tanida S, Mori Y, Toda M, Nakada H. CA125/MUC16 interacts with Src family kinases, and over-expression of its C-terminal fragment in human epithelial cancer cells reduces cell-cell adhesion. Eur J Cell Biol. 2013;92:257-63 pubmed publisher
    MUC16/CA125 is over-expressed in human epithelial tumors including ovarian, breast and some other carcinomas...

More Information

Publications88

  1. Chiu C, Shih Y, Tsai C, Liou J, Chen Y, Perng R. Serum tumor markers as predictors for survival in advanced non-small cell lung cancer patients treated with gefitinib. Lung Cancer. 2007;57:213-21 pubmed
    ..In gefitinib-treated NSCLC patients, correlation was good between 4-week TMR and IBR. Four-week TMR was predictive for survival. TMR may serve as a tool for assessing the gefitinib response in patients without measurable lesions. ..
  2. Yin B, Lloyd K. Molecular cloning of the CA125 ovarian cancer antigen: identification as a new mucin, MUC16. J Biol Chem. 2001;276:27371-5 pubmed
    b>CA125 is an ovarian cancer antigen that is the basis for a widely used serum assay for the monitoring of patients with ovarian cancer; however, detailed information on its biochemical and molecular nature is lacking...
  3. Rump A, Morikawa Y, Tanaka M, Minami S, Umesaki N, Takeuchi M, et al. Binding of ovarian cancer antigen CA125/MUC16 to mesothelin mediates cell adhesion. J Biol Chem. 2004;279:9190-8 pubmed
    ..The polypeptides encoded by the two cloned cDNA fragments matched to portions of CA125, an ovarian cancer antigen and a giant mucin-like glycoprotein present at the surface of tumor cells...
  4. Haridas D, Chakraborty S, Ponnusamy M, Lakshmanan I, Rachagani S, Cruz E, et al. Pathobiological implications of MUC16 expression in pancreatic cancer. PLoS ONE. 2011;6:e26839 pubmed publisher
    MUC16 (CA125) belongs to a family of high-molecular weight O-glycosylated proteins known as mucins...
  5. Gubbels J, Felder M, Horibata S, Belisle J, Kapur A, Holden H, et al. MUC16 provides immune protection by inhibiting synapse formation between NK and ovarian tumor cells. Mol Cancer. 2010;9:11 pubmed publisher
    ..MUC16, a carrier of the tumor marker CA125, has previously been shown to facilitate ovarian tumor metastasis and inhibits NK cell mediated lysis of tumor ..
  6. Govindarajan B, Gipson I. Membrane-tethered mucins have multiple functions on the ocular surface. Exp Eye Res. 2010;90:655-63 pubmed publisher
    ..Both animal and in vitro models for their study are herein described, as are alterations of the mucins in ocular surface disease...
  7. Lakshmanan I, Ponnusamy M, Das S, Chakraborty S, Haridas D, Mukhopadhyay P, et al. MUC16 induced rapid G2/M transition via interactions with JAK2 for increased proliferation and anti-apoptosis in breast cancer cells. Oncogene. 2012;31:805-17 pubmed publisher
    MUC16/CA125 is a tumor marker currently used in clinics for the follow-up of patients with ovarian cancer...
  8. Kaneko O, Gong L, Zhang J, Hansen J, Hassan R, Lee B, et al. A binding domain on mesothelin for CA125/MUC16. J Biol Chem. 2009;284:3739-49 pubmed publisher
    Ovarian cancer and malignant mesothelioma frequently express both mesothelin and CA125 (also known as MUC16) at high levels on the cell surface...
  9. Zhang S, Hu Y, Qian H, Jiao S, Liu Z, Tao H, et al. Expression and significance of ER, PR, VEGF, CA15-3, CA125 and CEA in judging the prognosis of breast cancer. Asian Pac J Cancer Prev. 2013;14:3937-40 pubmed
    ..of estrogen receptor (ER), progestrone receptor (PR), vascular endothelial growth factor (VEGF), CA15-3, CA125 and carcinoma embryonic antigen (CEA) expression in judging the prognosis of breast cancer...
  10. Thériault C, Pinard M, Comamala M, Migneault M, Beaudin J, Matte I, et al. MUC16 (CA125) regulates epithelial ovarian cancer cell growth, tumorigenesis and metastasis. Gynecol Oncol. 2011;121:434-43 pubmed publisher
    MUC16 (CA125) protein is a high molecular weight mucin overexpressed in the majority of epithelial ovarian cancers (EOC) but not in the epithelium of normal ovaries suggesting that it might play a role in EOC pathogenesis...
  11. Gipson I, Blalock T, Tisdale A, Spurr Michaud S, Allcorn S, Stavreus Evers A, et al. MUC16 is lost from the uterodome (pinopode) surface of the receptive human endometrium: in vitro evidence that MUC16 is a barrier to trophoblast adherence. Biol Reprod. 2008;78:134-42 pubmed
    ..These data indicate that MUC16 is a membrane component of the nonreceptive luminal uterine surface, which prevents cell adhesion, and that its removal during uterodome formation facilitates adhesion of the trophoblast. ..
  12. Gubbels J, Belisle J, Onda M, Rancourt C, Migneault M, Ho M, et al. Mesothelin-MUC16 binding is a high affinity, N-glycan dependent interaction that facilitates peritoneal metastasis of ovarian tumors. Mol Cancer. 2006;5:50 pubmed
    ..The demonstration that N-linked glycans are essential for mediating mesothlein-MUC16 binding may lead to novel therapeutic targets to control the spread of ovarian carcinoma. ..
  13. O Brien T, Beard J, Underwood L, Shigemasa K. The CA 125 gene: a newly discovered extension of the glycosylated N-terminal domain doubles the size of this extracellular superstructure. Tumour Biol. 2002;23:154-69 pubmed
    ..These additional data in association with our previous understanding of this molecule will provide the basis for our ability to understand the physiologic function of this molecule in biologic development and pathologic transformation. ..
  14. Davies J, Kirkham S, Svitacheva N, Thornton D, Carlstedt I. MUC16 is produced in tracheal surface epithelium and submucosal glands and is present in secretions from normal human airway and cultured bronchial epithelial cells. Int J Biochem Cell Biol. 2007;39:1943-54 pubmed
  15. Shimizu A, Hirono S, Tani M, Kawai M, Okada K, Miyazawa M, et al. Coexpression of MUC16 and mesothelin is related to the invasion process in pancreatic ductal adenocarcinoma. Cancer Sci. 2012;103:739-46 pubmed publisher
    ..In conclusion, we identified two specific genes, MUC16 and mesothelin, associated with the invasion process in patients with PDAC. ..
  16. Comamala M, Pinard M, Theriault C, Matte I, Albert A, Boivin M, et al. Downregulation of cell surface CA125/MUC16 induces epithelial-to-mesenchymal transition and restores EGFR signalling in NIH:OVCAR3 ovarian carcinoma cells. Br J Cancer. 2011;104:989-99 pubmed publisher
    ..The epithelial-to-mesenchymal transition (EMT) is a necessary step towards metastatic tumour progression. CA125/MUC16 mucin is a high-molecular-weight glycoprotein overexpressed in the majority of serous carcinomas, suggesting ..
  17. Yin B, Dnistrian A, Lloyd K. Ovarian cancer antigen CA125 is encoded by the MUC16 mucin gene. Int J Cancer. 2002;98:737-40 pubmed
    Serum assays based on the CA125 antigen are widely used in the monitoring of patients with ovarian cancer; however very little is known about the molecular nature of the CA125 antigen...
  18. Seeber B, Sammel M, Fan X, Gerton G, Shaunik A, Chittams J, et al. Panel of markers can accurately predict endometriosis in a subset of patients. Fertil Steril. 2008;89:1073-81 pubmed
    ..Using the serum concentration of four markers in a two-tiered decision rule, nearly half of the subjects in this population would have been diagnosed (and could have avoided surgery) with 93% accuracy. ..
  19. Kui Wong N, Easton R, Panico M, Sutton Smith M, Morrison J, Lattanzio F, et al. Characterization of the oligosaccharides associated with the human ovarian tumor marker CA125. J Biol Chem. 2003;278:28619-34 pubmed
    b>CA125 is a mucin commonly employed as a diagnostic marker for epithelial ovarian cancer...
  20. ARGUESO P, Tisdale A, Spurr Michaud S, Sumiyoshi M, Gipson I. Mucin characteristics of human corneal-limbal epithelial cells that exclude the rose bengal anionic dye. Invest Ophthalmol Vis Sci. 2006;47:113-9 pubmed
  21. Dorigo O, Berek J. Personalizing CA125 levels for ovarian cancer screening. Cancer Prev Res (Phila). 2011;4:1356-9 pubmed publisher
    ..Current screening modalities include pelvic examinations, transvaginal ultrasounds, and cancer antigen 125 (CA125) serum marker levels, which are associated with a high false-positive rate...
  22. Belisle J, Horibata S, Jennifer G, Petrie S, Kapur A, Andre S, et al. Identification of Siglec-9 as the receptor for MUC16 on human NK cells, B cells, and monocytes. Mol Cancer. 2010;9:118 pubmed publisher
    ..csMUC16) is shed in the extracellular milieu and is detected in the serum of cancer patients as the tumor marker CA125. csMUC16 acts as an adhesion molecule and facilitates peritoneal metastasis of ovarian tumors...
  23. Johnson M, Vito F, Xu H, Xu H. MUC16 expression and risk of adenocarcinoma metastases to peritoneum, pleura, leptomeninges, and brain. Appl Immunohistochem Mol Morphol. 2010;18:250-3 pubmed publisher
    ..Our findings suggest that adenocarcinomas with MUC16 expression may have an increased risk for metastases to pleura/peritoneum but not the leptomeninges or brain. ..
  24. O Brien T, Beard J, Underwood L, Dennis R, Santin A, York L. The CA 125 gene: an extracellular superstructure dominated by repeat sequences. Tumour Biol. 2001;22:348-66 pubmed
    ..Sequencing the gene provides us with the ability to initiate the quest to understand the biological function of CA 125. ..
  25. Ma S, Shen L, Qian N, Chen K. The prognostic values of CA125, CA19.9, NSE, AND SCC for stage I NSCLC are limited. Cancer Biomark. 2011;10:155-62 pubmed publisher
    ..Therefore, scientists only grafted the useful tumor markers, such as CA125, CA19.9, NSE, SCC, CEA and CYFRA21.1 which have been found in other solid tumors...
  26. Wang G, Qin Y, Zhang J, Zhao J, Liang Y, Zhang Z, et al. Nipple discharge of CA15-3, CA125, CEA and TSGF as a new biomarker panel for breast cancer. Int J Mol Sci. 2014;15:9546-65 pubmed publisher
    ..Serum biomarkers such as cancer antigen 15-3 (CA15-3), cancer antigen 125 (CA125), and carcinoembryonic antigen (CEA) can be used as diagnostic and prognostic factors and can also provide ..
  27. Wang L, Zhang F, Cui J, Chen L, Chen Y, Liu B. CAFs enhance paclitaxel resistance by inducing EMT through the IL?6/JAK2/STAT3 pathway. Oncol Rep. 2018;39:2081-2090 pubmed publisher
    ..Univariate and multivariate analyses revealed that age, CA125, interstitial IL?6 expression and cytoreduction satisfaction were closely related to the sensitivity of the TP (..
  28. Ando H, Watanabe Y, Ogawa M, Tamura H, Deguchi T, Ikeda K, et al. Mesonephric adenocarcinoma of the uterine corpus with intracystic growth completely confined to the myometrium: a case report and literature review. Diagn Pathol. 2017;12:63 pubmed publisher
    ..b>CA125 and CA19-9 antigen expression was also detected...
  29. Luzak A, Schnell Inderst P, Bühn S, Mayer Zitarosa A, Siebert U. Clinical effectiveness of cancer screening biomarker tests offered as self-pay health service: a systematic review. Eur J Public Health. 2016;26:498-505 pubmed publisher
    ..Only one trial, which simultaneously assessed cancer antigen 125 (CA125) and vaginal ultrasound for ovarian cancer screening, provided the outcome of interest...
  30. Senol T, Polat M, Ozkaya E, Karateke A. Tumor Diameter for Prediction of Recurrence, Disease Free and Overall Survival in Endometrial Cancer Cases. Asian Pac J Cancer Prev. 2015;16:7463-6 pubmed
    ..using a prospectively collected database including age, smoking history, menopausal status, body mass index, CA125, systemic disorders, tumor histology, tumor grade, lymphovascular space invasion, tumor diameter, cervical ..
  31. Williams K, Terry K, Tworoger S, Vitonis A, Titus L, Cramer D. Polymorphisms of MUC16 (CA125) and MUC1 (CA15.3) in relation to ovarian cancer risk and survival. PLoS ONE. 2014;9:e88334 pubmed publisher
    To examine single nucleotide polymorphism (SNPs) in MUC16 (CA125) and MUC1 (CA15.3) in relation to ovarian cancer risk and survival...
  32. Sabbatini P, Mooney D, Iasonos A, Thaler H, Aghajanian C, Hensley M, et al. Early CA-125 fluctuations in patients with recurrent ovarian cancer receiving chemotherapy. Int J Gynecol Cancer. 2007;17:589-94 pubmed
    ..Discontinuation of therapy solely on the basis of early CA-125 increase (precycle 3), particularly with liposomal doxorubicin chemotherapy, may exclude some patients who will benefit from continued therapy. ..
  33. Homma S, Satoh H, Kagohashi K, Fujiwara M, Kamma H, Sekizawa K. Production of CA125 by human lung cancer cell lines. Clin Exp Med. 2004;4:139-41 pubmed
    b>CA125, which until recently was considered an ovary specific tumor marker, is elevated in the serum of patients with many pathological conditions, including lung cancer...
  34. Antonini Canterin F, Popescu B, Popescu A, Beladan C, Korcova R, Piazza R, et al. Heart failure in patients with aortic stenosis: clinical and prognostic significance of carbohydrate antigen 125 and brain natriuretic peptide measurement. Int J Cardiol. 2008;128:406-12 pubmed
    ..Carbohydrate antigen 125 (CA125) demonstrated recently a BNP-like behaviour in patients with congestive heart failure (CHF) but has never been ..
  35. Romagnolo C, Leon A, Fabricio A, Taborelli M, Polesel J, Del Pup L, et al. HE4, CA125 and risk of ovarian malignancy algorithm (ROMA) as diagnostic tools for ovarian cancer in patients with a pelvic mass: An Italian multicenter study. Gynecol Oncol. 2016;141:303-311 pubmed publisher
    This multicenter study aims to evaluate HE4, CA125 and risk of ovarian malignancy algorithm (ROMA) performance in the differential diagnosis of epithelial ovarian cancer (EOC)...
  36. Karlsen M, Fagö Olsen C, Høgdall E, Schnack T, Christensen I, Nedergaard L, et al. A novel index for preoperative, non-invasive prediction of macro-radical primary surgery in patients with stage IIIC-IV ovarian cancer-a part of the Danish prospective pelvic mass study. Tumour Biol. 2016;37:12619-12626 pubmed
    ..Serum human epididymis protein 4 (HE4), serum cancer antigen 125 (CA125), age, performance status, and presence/absence of ascites at ultrasonography were evaluated individually and ..
  37. Refiker M, Yilmaz M. Association of right heart with CA-125 levels in patients with heart failure. Int J Cardiol. 2010;145:521-2 pubmed publisher
  38. Feng F, Tian Y, Xu G, Liu Z, Liu S, Zheng G, et al. Diagnostic and prognostic value of CEA, CA19-9, AFP and CA125 for early gastric cancer. BMC Cancer. 2017;17:737 pubmed publisher
    ..antigen (CEA), carbohydrate associated antigen 19-9 (CA19-9), alpha-fetoprotein (AFP) and cancer antigen 125 (CA125) in early gastric cancer have not been investigated yet...
  39. Yang W, Gentry Maharaj A, Simmons A, Ryan A, Fourkala E, Lu Z, et al. Elevation of TP53 Autoantibody Before CA125 in Preclinical Invasive Epithelial Ovarian Cancer. Clin Cancer Res. 2017;23:5912-5922 pubmed publisher
    ..Among 164 cases with rising CA125 detected with the UKCTOCS risk of ovarian cancer algorithm (ROCA), 20.7% had elevated TP53 autoantibody...
  40. Gong S, Chen Y, Zhang Y, Yao W, Chen L, Liu S, et al. [Diagnostic value of CA125, HE4 and Copenhagen Index in differentiating benign from malignant epithelial ovarian tumors]. Nan Fang Yi Ke Da Xue Xue Bao. 2017;37:628-632 pubmed
    To analyze diagnostic value of Copenhagen Index based on pretreatment serum CA125, HE4 and age in differentiating benign and malignant epithelial ovarian tumors...
  41. Zhu Y, He L, Zhang Z, Huang Q. Expression of serum human epididymal secretory protein E4 at low grade and high grade serous carcinomas. Asian Pac J Trop Med. 2012;5:925-30 pubmed publisher
    ..ovarian cancer were diagnosed by the two-tier grade system, serum levels of HE4 and carbohydrate antigen 125 (CA125) were measured by ELISA and radioisotope method, respectively in 60 serous ovarian cancer patients...
  42. Wang W, Xu X, Tian B, Wang Y, Du L, Sun T, et al. The diagnostic value of serum tumor markers CEA, CA19-9, CA125, CA15-3, and TPS in metastatic breast cancer. Clin Chim Acta. 2017;470:51-55 pubmed publisher
    ..value of serum tumor markers carcinoembryonic antigen (CEA), cancer antigen 19-9 (CA19-9), cancer antigen 125 (CA125), cancer antigen 15-3 (CA15-3), and tissue polypeptide-specific antigen (TPS) in metastatic breast cancer (MBC)...
  43. Leung F, Bernardini M, Brown M, Zheng Y, Molina R, Bast R, et al. Validation of a Novel Biomarker Panel for the Detection of Ovarian Cancer. Cancer Epidemiol Biomarkers Prev. 2016;25:1333-40 pubmed publisher
    ..KLK6, FOLR1, CA125, and HE4 were investigated in three independent serum cohorts with a total of 20 healthy controls, 150 benign ..
  44. Katagiri H, Nakayama K, Razia S, Nakamura K, Sato E, Ishibashi T, et al. Loss of autophagy-related protein Beclin 1 may define poor prognosis in ovarian clear cell carcinomas. Int J Oncol. 2015;47:2037-44 pubmed publisher
    ..There was no significant correlation between loss of Beclin 1 expression and FIGO stage, CA125 levels, patient age, status of endometriosis, Ki-67 labeling index, chemotherapy regimen or status of residual ..
  45. Abdalla N, Piorkowski R, Stanirowski P, Cendrowski K, Sawicki W. Can Replacing CA125 with HE4 in Risk of Malignancy Indices 1-4 Improve Diagnostic Performance in the Presurgical Assessment of Adnexal Tumors?. Biomed Res Int. 2017;2017:6712376 pubmed publisher
    To assess whether replacing CA125 with HE4 in the classical formulas of risk of malignancy indices (RMIs) can improve diagnostic performance.
  46. Crăciun M, Domsa I. Immunohistochemical diagnosis of Krukenberg tumors. Rom J Morphol Embryol. 2017;58:845-849 pubmed
    ..The analysis of immunohistochemical profiles for CEA and CA125 showed that, regardless of the histological origin, the predominant immunohistochemical profile was CEA(+)÷CA125(-..
  47. Imai K, Kato H, Katayama K, Nakanishi K, Kawano A, Iura A, et al. A preoperative risk-scoring system to predict lymph node metastasis in endometrial cancer and stratify patients for lymphadenectomy. Gynecol Oncol. 2016;142:273-7 pubmed publisher
    ..The KCC classified patients for LNM risk based on tumor volume, myometrial invasion, histological grade, and serum CA125 levels, while YCU used only myometrial invasion...
  48. Ferriss J, Java J, Bookman M, Fleming G, Monk B, Walker J, et al. Ascites predicts treatment benefit of bevacizumab in front-line therapy of advanced epithelial ovarian, fallopian tube and peritoneal cancers: an NRG Oncology/GOG study. Gynecol Oncol. 2015;139:17-22 pubmed publisher
    ..001); serous histology (p=0.012); higher baseline CA125 (p<0.001); and suboptimal cytoreduction (p=0.004)...
  49. Combe P, Chauvenet L, Lefrère Belda M, Blons H, Rousseau C, Oudard S, et al. Sustained response to vemurafenib in a low grade serous ovarian cancer with a BRAF V600E mutation. Invest New Drugs. 2015;33:1267-70 pubmed publisher
    ..We saw impressive efficacy, with a long-term partial response along with CA125 reductions and symptom relief...
  50. Zohny S, Fayed S. Clinical utility of circulating matrix metalloproteinase-7 (MMP-7), CC chemokine ligand 18 (CCL18) and CC chemokine ligand 11 (CCL11) as markers for diagnosis of epithelial ovarian cancer. Med Oncol. 2010;27:1246-53 pubmed publisher
    ..4%. Our data indicate that serum MMP-7, CCL18 and CCL11, in combination with CA 125 could be useful in diagnosis of EOC. ..
  51. Tiersten A, Liu P, Smith H, Wilczynski S, Robinson W, Markman M, et al. Phase II evaluation of neoadjuvant chemotherapy and debulking followed by intraperitoneal chemotherapy in women with stage III and IV epithelial ovarian, fallopian tube or primary peritoneal cancer: Southwest Oncology Group Study S0009. Gynecol Oncol. 2009;112:444-9 pubmed publisher
    ..IV) paclitaxel 175 mg/m2 and carboplatin AUC 6 q 21 daysx3 cycles followed by surgery (if >/=50% decrease in CA125)...
  52. Yucel H, Kaya H, Zorlu A, Yıldırımlı K, Sancakdar E, Gunes H, et al. Cancer antigen 125 levels and increased risk of new-onset atrial fibrillation. Herz. 2015;40 Suppl 2:119-24 pubmed publisher
    ..CA-125 level is associated with the development of AF in patients with hospitalized systolic HF. ..
  53. Creaney J, Dick I, Dare H, Demelker Y, Nowak A, Musk A, et al. Does CA125 binding to mesothelin impact the detection of malignant mesothelioma?. Lung Cancer. 2013;80:39-44 pubmed publisher
    ..It has high specificity but a sensitivity of only 50%. As mesothelin binds CA125, and as CA125 is often elevated in MM, we asked whether this binding affected measurable mesothelin levels in a ..
  54. Togami S, Nomoto M, Higashi M, Goto M, Yonezawa S, Tsuji T, et al. Expression of mucin antigens (MUC1 and MUC16) as a prognostic factor for mucinous adenocarcinoma of the uterine cervix. J Obstet Gynaecol Res. 2010;36:588-97 pubmed publisher
    ..50, 95% CI = 0.82-87.4, P < 0.05). The expressions of MUC1 and/or MUC16 may be available as independent prognostic factors for the endocervical type of mucinous adenocarcinoma. ..
  55. Lu J, Zheng Z, Zhang Q, Li G, Li F, Le Z, et al. Measurement of HE4 and CA125 and establishment of reference intervals for the ROMA index in the sera of pregnant women. J Clin Lab Anal. 2017;: pubmed publisher
    Cancer antigen 125 (CA125) and human epididymis protein 4 (HE4) are biomarkers for ovarian cancer. Their specificity and sensitivity are often limited during pregnancy as a result of great fluctuations...
  56. Zhao L, Ma Z. Facile synthesis of polyaniline-polythionine redox hydrogel: Conductive, antifouling and enzyme-linked material for ultrasensitive label-free amperometric immunosensor toward carcinoma antigen-125. Anal Chim Acta. 2018;997:60-66 pubmed publisher
    ..an ultrasensitive and protein-resistant label-free amperometric immunosening platform for carcinoma antigen-125 (CA125) based on redox polyaniline-polythionine hydrogel (PANI-PThi gel) was developed...
  57. May T, Stewart J, Bernardini M, Ferguson S, Laframboise S, Jiang H, et al. The prognostic value of perioperative, pre-systemic therapy CA125 levels in patients with high-grade serous ovarian cancer. Int J Gynaecol Obstet. 2017;: pubmed publisher
    To investigate the ability of preoperative CA125 and post-surgical CA125 changes to predict outcomes among patients with high-grade serous ovarian cancer (HGSC).
  58. Cho S, Cho H, Nam A, Kim H, Choi Y, Park K, et al. Neutrophil-to-lymphocyte ratio as an adjunct to CA-125 for the diagnosis of endometriosis. Fertil Steril. 2008;90:2073-9 pubmed publisher
    ..3%) had their serum CA-125 levels at more than 35 IU/mL. Measurement of NLR and the combined marker may be used as simple and easily obtained diagnostic markers for endometriosis. ..
  59. Husser O, Nunez J, Nunez E, Holzamer A, Camboni D, Luchner A, et al. Tumor marker carbohydrate antigen 125 predicts adverse outcome after transcatheter aortic valve implantation. JACC Cardiovasc Interv. 2013;6:487-96 pubmed publisher
    This study sought to predict the value of tumor marker carbohydrate antigen 125 (CA125) before and after transcatheter aortic valve implantation (TAVI) for all-cause death and a composite endpoint of death, admission for heart failure, ..
  60. Mano A, Falcão A, Godinho I, Santos J, Leitão F, de Oliveira C, et al. CA-125 AUC as a predictor for epithelial ovarian cancer relapse. Cancer Biomark. 2008;4:73-81 pubmed
    ..85) and with a substantial mean lead time to relapse (181 days). If a negative answer was obtained then Criterion B should performed to confirm the absence of relapse. ..
  61. Kil K, Chung J, Pak H, Jeung I, Kim J, Jo H, et al. Usefulness of CA125 in the differential diagnosis of uterine adenomyosis and myoma. Eur J Obstet Gynecol Reprod Biol. 2015;185:131-5 pubmed publisher
    To evaluate the usefulness of CA125 levels in the differential diagnosis of adenomyosis and myoma. This has been addressed by few, if any, previous studies...
  62. Fang S, Zhang H, Wang C, Zhang Y. Serum CA125 and NSE: biomarkers of disease severity in patients with silicosis. Clin Chim Acta. 2014;433:123-7 pubmed publisher
    ..Both serum NSE and CA125 concentrations were significantly higher in cases compared with controls...
  63. Baskic D, Ristic P, Matić S, Bankovic D, Popovic S, Arsenijevic N. Clinical evaluation of the simultaneous determination of CA 15-3, CA 125 and sHER2 in breast cancer. Biomarkers. 2007;12:657-67 pubmed
    ..Our findings indicate that measurement of CA 15-3 serum values in conjunction with sHER2 and CA 15-3 can increase sensitivity in metastasis detection. ..
  64. Seo K, Chung S, Lee J, Park M, Kim E. Regulation of membrane-associated mucins in the human corneal epithelial cells by dexamethasone. Cornea. 2007;26:709-14 pubmed
    ..This study shows that MUC1, MUC4, and MUC16 are regulated differently by dexamethasone in human corneal epithelial cells. External application of dexamethasone might affect the precorneal mucin. ..
  65. van Altena A, Holtsema H, Hendriks J, Massuger L, De Hullu J. Cancer antigen 125 level after a bilateral salpingo-oophorectomy: what is the contribution of the ovary to the cancer antigen 125 level?. Menopause. 2011;18:133-7 pubmed publisher
    ..We evaluated the effect of BSO on CA125 level in BRCA mutation carriers and tested which factors interact with the change in CA125 level...
  66. Wang W, Somers E, Ross E, Kline J, O Shannessy D, Schweizer C, et al. FCGR2A and FCGR3A Genotypes Correlate with Farletuzumab Response in Patients with First-Relapsed Ovarian Cancer Exhibiting Low CA125. Cytogenet Genome Res. 2017;: pubmed publisher
    ..3 trial in ovarian cancer patients treated with carboplatin/taxane plus farletuzumab found that the tumor-produced CA125 protein can suppress farletuzumab function via perturbing its engagement to the activating Fc-? receptors CD32a (..
  67. Won E, Hurria A, Feng T, Mohile S, Owusu C, Klepin H, et al. CA125 level association with chemotherapy toxicity and functional status in older women with ovarian cancer. Int J Gynecol Cancer. 2013;23:1022-8 pubmed publisher
    Older women with ovarian cancer have increased cancer-related mortality and chemotherapy toxicity. CA125 is a sensitive biomarker for tumor burden...
  68. Moore R, Miller M, Steinhoff M, Skates S, Lu K, Lambert Messerlian G, et al. Serum HE4 levels are less frequently elevated than CA125 in women with benign gynecologic disorders. Am J Obstet Gynecol. 2012;206:351.e1-8 pubmed publisher
    The human epididymis protein 4 (HE4) is a novel biomarker for ovarian cancer. This study measured the HE4 and CA125 levels in women with benign gynecological disorders...
  69. Shen A, Xu S, Ma Y, Guo H, Li C, Yang C, et al. Diagnostic value of serum CA125, CA19-9 and CA15-3 in endometriosis: A meta-analysis. J Int Med Res. 2015;43:599-609 pubmed publisher
    ..Case-control studies evaluating CA125, CA19-9 and CA15-3 and endometriosis, published between January 2000 and November 2014 were retrieved from PubMed(..
  70. Lan Z, Fu D, Yu X, Xi M. Diagnostic values of osteopontin combined with CA125 for ovarian cancer: a meta-analysis. Fam Cancer. 2016;15:221-30 pubmed publisher
    ..for OC and determine the overall diagnostic accuracy of OPN measurement when combined with cancer antigen 125 (CA125)...
  71. Fang C, Cao Y, Liu X, Zeng X, Li Y. Serum CA125 is a predictive marker for breast cancer outcomes and correlates with molecular subtypes. Oncotarget. 2017;8:63963-63970 pubmed publisher
    ..This study aims to investigate the role of preoperative serum tumor markers (CEA, CA125 and CA15-3) in the management of breast cancer, and their relationships with patients' clinicopathological ..
  72. Noonan S, Patil T, Gao D, King G, Thibault J, Lu X, et al. Baseline and On-Treatment Characteristics of Serum Tumor Markers in Stage IV Oncogene-Addicted Adenocarcinoma of the Lung. J Thorac Oncol. 2018;13:134-138 pubmed publisher
    ..A single-center retrospective analysis of available carcinoembryonic antigen, CA125, CA19.9, and CA27...
  73. Xu H, Liu L, Xiang J, Wang W, Qi Z, Wu C, et al. Postoperative serum CEA and CA125 levels are supplementary to perioperative CA19-9 levels in predicting operative outcomes of pancreatic ductal adenocarcinoma. Surgery. 2017;161:373-384 pubmed publisher
    ..Perioperative CA19-9 and postoperative serum markers (CEA, CA242, CA72-4, CA50, CA125, CA153, and AFP) were investigated...
  74. Yamamoto Furusho J, Ascaño Gutiérrez I, Furuzawa Carballeda J, Fonseca Camarillo G. Differential Expression of MUC12, MUC16, and MUC20 in Patients with Active and Remission Ulcerative Colitis. Mediators Inflamm. 2015;2015:659018 pubmed publisher
    ..003, OR = 0.37). Conclusions. An increased gene expression of MUC16 and MUC20 was found in patients with remission UC. ..
  75. Chen L, Zhang Y, Chen M, Chen J. [Prognostic value of carcinoembryonic antigen, alpha fetoprotein, carbohydrate antigen 125 and carbohydrate antigen 19-9 in gastroenteropancreatic neuroendocrine neoplasms]. Zhonghua Wei Chang Wai Ke Za Zhi. 2017;20:1002-1008 pubmed
    ..of digestive tumors, including carcinoembryonic antigen (CEA), alpha fetoprotein (AFP), carbohydrate antigen 125 (CA125) and carbohydrate antigen 19-9 (CA19-9), in gastroenteropancreatic neuroendocrine neoplasm (GEP-NEN) and their ..
  76. Sangoi A, Higgins J, Rouse R, Schneider A, McKenney J. Immunohistochemical comparison of MUC1, CA125, and Her2Neu in invasive micropapillary carcinoma of the urinary tract and typical invasive urothelial carcinoma with retraction artifact. Mod Pathol. 2009;22:660-7 pubmed publisher
    ..and 24 case controls of invasive urothelial carcinoma with retraction artifact using monoclonal antibodies MUC1, CA125, and Her2Neu...
  77. Li L, Xu Y, Yu C. Proteomic analysis of serum of women with elevated Ca-125 to differentiate malignant from benign ovarian tumors. Asian Pac J Cancer Prev. 2012;13:3265-70 pubmed
    ..A novel protein, APOA4, has the potential to be a marker for malignant tumor differentiation in the serum of women with elevated CA-125. ..
  78. Howell N, Zheng W, Cheng L, Tornos C, Kane P, Pearl M, et al. Carcinomas of ovary and lung with clear cell features: can immunohistochemistry help in differential diagnosis?. Int J Gynecol Pathol. 2007;26:134-40 pubmed
    ..Our results suggest that an immunohistochemical panel consisting of TTF-1, CEA, CA-125, and OCT-4 is helpful in distinguishing most pulmonary and ovarian carcinomas with clear cell features. ..
  79. Judson K, McCormick C, Vang R, Yemelyanova A, Wu L, Bristow R, et al. Women with undiagnosed colorectal adenocarcinomas presenting with ovarian metastases: clinicopathologic features and comparison with women having known colorectal adenocarcinomas and ovarian involvement. Int J Gynecol Pathol. 2008;27:182-90 pubmed publisher